Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease

Yılmaz, Yusuf; Yönal, Oya; Kurt, Ramazan; Alahdab, Yeşim Özen; Eren, Fatih; Özdoğan, Osman; Çelikel, Çiğdem; İmeryüz, Neşe; Kalaycı, Cem; Avşar, Erol

doi:10.3109/00365521.2010.516452

Cited by 108 publications

(121 citation statements)

References 28 publications

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…Studies have shown that omentin-1 levels are usually reduced in patients with IR, but there are some different findings in the literature. Yilmaz et al 35 reported that omentin-1 was significantly increased in patients with nonalcoholic fatty liver disease in which IR is highly prevalent. Furthermore, treatment with metformin and pioglitazone, insulin sensitizing drugs, reduced the levels of omentin-1 in patients with newly diagnosed diabetes in spite of the fact that a significant improvement in HOMA-IR were found in another study.…”

Section: Discussionmentioning

confidence: 99%

Serum omentin-1, inflammation and carotid atherosclerosis in patients with non-diabetic chronic kidney disease

Şengül¹,

Duygulu²,

Dindar³

et al. 2013

Renal Failure

View full text Add to dashboard Cite

Background and aim: Omentin-1 is suggested to affect inversely atherosclerosis (AS). Data about omentin-1 is limited to chronic kidney disease (CKD). Our aim was to examine omentin-1 in non-diabetic CKD patients who are not dialyzed and investigate its relationships with inflammation and carotid AS. Materials and Methods: We performed a cross-sectional study in 55 non-diabetic CKD patients and 30 healthy controls. Baseline clinical and laboratory data were obtained for all participants. Serum omentin-1 and interleukin-6 (IL-6) levels were measured according to the manufacturer's instructions. Carotic plaque and intima-media thickness (IMT) were assessed by carotid ultrasonography. The homeostasis model assessment of insulin resistance index (HOMA-IR) was used to assess IR. Results: Omentin-1 and IL-6 levels in the patient group were found to be higher than the control group; the differences were statistically significant (p ¼ 0.01 and p ¼ 0.04, respectively). Carotid IMT(mean) was significantly higher in the patient group (p ¼ 0.01). Omentin-1 did not correlate with IL-6 and IMT in the patient group (p ¼ 0.51 and p ¼ 0.76, respectively). In subgroup analysis, omentin-1 levels in patients with carotid plaque were lower than those without carotid plaque (179.5 AE 88.1 ng/ml and 185.9 AE 67.8 ng/ml, respectively). However, the difference was not statistically significant (p ¼ 0.47). Conclusion: We conclude that omentin-1 is higher in not dialyzed non-diabetic CKD and there is no correlation between omentin-1 and IL-6 or carotid IMT(mean).

show abstract

Section: Discussionmentioning

confidence: 99%

Serum omentin-1, inflammation and carotid atherosclerosis in patients with non-diabetic chronic kidney disease

Şengül¹,

Duygulu²,

Dindar³

et al. 2013

Renal Failure

View full text Add to dashboard Cite

show abstract

“…An association of circulating chemerin levels with the markers of NAFLD has also been highlighted, but the results have been inconsistent in terms of some of the investigated histological features (28,30,31).…”

Section: Introductionmentioning

confidence: 99%

Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease

Döcke

Lock

Birkenfeld

et al. 2013

European Journal of Endocrinology

118

View full text Add to dashboard Cite

Objective: Adipose tissue-derived factors link non-alcoholic fatty liver disease (NAFLD) with obesity, which has also been reported for circulating chemerin. On the other hand, hepatic chemerin and chemokine-like receptor 1 (CMKLR1) mRNA expression has not yet been studied in an extensively characterized patient collective. Design: This study was cross-sectional and experimental in design. Methods: Liver tissue samples were harvested from 47 subjects and histologically examined according to the NAFLD activity score (NAS). The concentrations of chemerin and CMKLR1 were measured using semi-quantitative real-time PCR, and the concentration of serum chemerin was measured using ELISA. To evaluate potential effects of chemerin and CMKLR1, cultured primary human hepatocytes (PHHs) were exposed to selected metabolites known to play a role in NAFLD (insulin, glucagon, palmitoic acid, and interleukin-6 (IL6)). Results: Chemerin and CMKLR1 mRNA levels were elevated in the human liver. Their expression was correlated with the NAS (R 2 Z0.543; P!0.001 and R 2 Z0.355; PZ0.014 respectively) and was significantly elevated in patients with definite non-alcoholic steatohepatitis (NASH) (P!0.05 respectively). Linear regression analysis confirmed an independent association of liver fibrosis, steatosis, inflammation, and hepatocyte ballooning with hepatic chemerin mRNA expression (P!0.05 respectively). The expression of hepatic chemerin and CMKLR1 was correlated with the measures of obesity (P!0.05). The incubation of PHHs with IL6 significantly increased the expression of CMKLR1 mRNA (PZ0.027), while that of chemerin remained unaffected (PO0.05). None of the other metabolites showed an influence (PO0.05). Conclusion: This is the first study to show that chemerin mRNA expression is significantly elevated in the liver of NASH patients and that CMKLR1 expression is upregulated in liver inflammation, whereby IL6 could play a causal role.

show abstract

“…We detected that omentin levels are increased with loss of weight contrary to literature. NAFLD may be a confounder; so that, we suggest additional studies to identify reasons for this paradoxical increase as proposition of Yılmaz et al (26).…”

Section: Methodsmentioning

confidence: 80%

“…Reduced omentin levels in patients with diabetes are also observed (24,25). Interestingly, Yılmaz et al showed that serum omentin levels are raised in patients with NAFLD, omentin levels are positively associated with hepatocyte ballooning -indicator of hepatocyte degeneration-independent of insulin resistance and some features of the metabolic syndrome (26). They also hypothesized that omentin might play a role in the development and progression of NAFLD.…”

Section: Methodsmentioning

confidence: 98%

Comparative effectiveness of diet alone and diet plus metformin treatment on omentin levels in type 2 diabetes patients with nonalcoholic fatty liver disease: a prospective randomized trial

Arslan¹,

Ulaş²,

Karakaş³

et al. 2017

Period Biol

View full text Add to dashboard Cite

Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease

Abstract: Our results suggest that serum omentin levels are raised in patients with NAFLD regardless of potential confounders and represent an independent predictor of hepatocyte ballooning.

Cited by 108 publications

References 28 publications

Serum omentin-1, inflammation and carotid atherosclerosis in patients with non-diabetic chronic kidney disease

Serum omentin-1, inflammation and carotid atherosclerosis in patients with non-diabetic chronic kidney disease

Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease

Comparative effectiveness of diet alone and diet plus metformin treatment on omentin levels in type 2 diabetes patients with nonalcoholic fatty liver disease: a prospective randomized trial

Contact Info

Product

Resources

About